A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers.
However, the drastic reduction, especially in API prices from Chinese sources, has raised alarm bells within the Indian pharmaceutical industry, with experts fearing it signals a predatory pricing strategy, reports The Pharma Letter’s India correspondent.
Domestic pharma majors allege that these steep reductions are a strategic move by Chinese suppliers to undercut Indian API manufacturers and cement China's stronghold in the market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze